Malignancy in systemic lupus erythematosus
Malignancy in systemic lupus erythematosus
复制标题
DOI：
10.1002/art.1780390625
复制
发表时间：
1996-06-01
影响因子：
--
通讯作者：
Urowitz, MB
中科院分区：
文献类型：
--
作者：
AbuShakra, M;Gladman, DD;Urowitz, MB
客观的。评估系统性红斑狼疮 (SLE) 患者患癌症的风险。方法。多伦多大学狼疮诊所对 SLE 患者 (n 724) 进行了 24 年的前瞻性随访，通过组织学或尸检报告证实了癌症的诊断，使用标准化癌症发生率和标准化发病率 (SIR)（观察到的癌症与预期癌症的比率）来估计癌症风险。结果。在 7,233 患者年的随访中，23 名 SLE 患者 (3.2%) 发现了 24 种癌症。与安大略省人群相比，狼疮队列中所有癌症的总体估计风险并未增加（SIR 1.08，95%置信区间 0.70-1.62），观察到血液系统癌症的风险增加了 4.1 倍，主要是由于非霍奇金淋巴瘤的风险增加。与类风湿性关节炎（RA）和系统性硬化症患者相比，SLE 队列中的癌症风险显着降低（SSc）。结论。与 RA 和 SSc 相比，SLE 与所有癌症的风险较低相关，但与一般人群相比，非霍奇金淋巴瘤的风险增加。
Objective. To estimate the risk of cancer in patients with systemic lupus erythematosus (SLE).Methods. Patients with SLE (n 724) have been followed prospectively, for 24 years, at the University of Toronto Lupus Clinic, The diagnosis of cancer was confirmed by histologic or autopsy reports, Standardized rates of cancer and standardized incidence rates (SIR) (ratio of observed-to-expected cancers) were used to estimate the risk for cancers.Results. Twenty-four cancers were identified in 23 SLE patients (3.2%) during 7,233 patient-years of followup. Compared with the Ontario population, the overall estimated risk for all cancers was not increased in the lupus cohort (SIR 1.08, 95% confidence interval 0.70-1.62), A 4.1-fold increased risk for hematologic cancers was observed, due mainly to an increased risk of non-Hodgkin's lymphoma, The risk for cancer was significantly lower in the SLE cohort compared with patients with rheumatoid arthritis (RA) and systemic sclerosis (SSc).Conclusion. SLE is associated with a lower risk of all cancers compared with RA and SSc, but an increased risk for non-Hodgkin's lymphoma compared with the general population.